Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Otherwise Healthy Overweight or Obese Clear all
Completed Not applicable Interventional Accepts healthy volunteers

To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

NCT05963594
View directory record Official record
Conditions
Dietary Supplement
Interventions
Oligomalt, maltodextrin
Dietary Supplement
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 26, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

NCT03775278
View directory record Official record
Conditions
Otherwise Healthy Overweight or Obese
Interventions
PHP-303, Placebo
Drug · Other
Lead sponsor
pH Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jun 26, 2026, 1:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pistachio Snacking and Metabolic Flexibility

NCT07340125
View directory record Official record
Conditions
Overweight (BMI > 25), Obese But Otherwise Healthy Participants, Overweight or Obese, Obese Patients (BMI ≥ 30 kg/m²), Poor Sleep Quality, Healthy Participants, Physically Inactive
Interventions
Pistachio
Other
Lead sponsor
University of South Carolina
Other
Eligibility
25 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 26, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

NCT04839393
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 26, 2026, 1:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

NCT07224399
View directory record Official record
Conditions
Healhty, Overweight or Obesity
Interventions
BGM1812, Placebo
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 26, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

NCT06567327
View directory record Official record
Conditions
Obesity
Interventions
Danuglipron, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jun 26, 2026, 1:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

NCT06857617
View directory record Official record
Conditions
Obesity and Overweight
Interventions
(Part C) MET097, (Part C) Placebo
Biological
Lead sponsor
Metsera, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 26, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCT06440980
View directory record Official record
Conditions
Healthy, Obese, Overweight, Obesity
Interventions
Orforglipron
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Anaheim, California • Los Alamitos, California • Daytona Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jun 26, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MET233 in Individuals With Obesity or Overweight

NCT07022977
View directory record Official record
Conditions
Obesity and Overweight
Interventions
MET233, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 26, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

NCT06568731
View directory record Official record
Conditions
Obesity
Interventions
Danuglipron
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jun 26, 2026, 1:43 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07654972
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY4174794, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 26, 2026, 1:43 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 26, 2026, 1:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07225556
View directory record Official record
Conditions
Overweight, Obesity
Interventions
LY4167586, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 26, 2026, 1:43 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

NCT06910839
View directory record Official record
Conditions
Overweight, Obesity
Interventions
PF-07976016, PF-06882961
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 26, 2026, 1:43 AM EDT